Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Recent Patents on Anti-Cancer Drug Discovery

Volume 6 Issue 3
ISSN: 1574-8928
eISSN: 2212-3970

 

   All Titles

  Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
  pp.311-323 (13) Authors: Sarah Shirley, Alexandre Morizot, Olivier Micheau
 
 
      Abstract

The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.

 
  Keywords: chemotherapy, death domain, death effector domain, DISC, FADD, c-FLIP,, scaffold, TRAIL, TRAIL-R4, APO2-L
  Affiliation: INSERM, U866, Dijon, F- 21079 France; Faculty of Medicine and Pharmacy, University of Bourgogne, Dijon, F-21079 France.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers